Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 2Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 69Carcinoma, Non-Small-Cell Lung 41Carcinoma, Renal Cell 38Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 14Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Myelodysplastic Syndromes 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Multiple Myeloma 5Mesothelioma, Malignant 5

Interventions

pembrolizumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 4cabozantinib 3Nivolumab 3cemiplimab 2Ipilimumab 2sodium thiosulfate 1relacorilant 1lenvatinib 1fludarabine phosphate 1dostarlimab 1Radiation 1Mitotane 1Interleukin-13 1Fluorodeoxyglucose F18 1Floxuridine 1E-7386 1Drug Therapy 1Dexamethasone 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1Cisplatin 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adrenocortical Carcinoma × Ipilimumab × 1 year × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡